Inhibikase Therapeutics Debt
IKT Stock | USD 2.34 0.03 1.30% |
Inhibikase Therapeutics holds a debt-to-equity ratio of 0.006. At this time, Inhibikase Therapeutics' Short Term Debt is comparatively stable compared to the past year. Debt To Equity is likely to gain to 0.04 in 2024, whereas Short and Long Term Debt is likely to drop slightly above 124.7 K in 2024. . Inhibikase Therapeutics' financial risk is the risk to Inhibikase Therapeutics stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Inhibikase Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Inhibikase Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Inhibikase Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Inhibikase Therapeutics' stakeholders.
For most companies, including Inhibikase Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Inhibikase Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Inhibikase Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 26.456 | Book Value 1.775 | Operating Margin (238.85) | Return On Assets (0.76) | Return On Equity (1.50) |
Inhibikase |
Inhibikase Therapeutics Bond Ratings
Inhibikase Therapeutics financial ratings play a critical role in determining how much Inhibikase Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Inhibikase Therapeutics' borrowing costs.Piotroski F Score | 4 | Poor | View |
Beneish M Score | (3.45) | Unlikely Manipulator | View |
Inhibikase Therapeutics Debt to Cash Allocation
Inhibikase Therapeutics has 622 K in debt with debt to equity (D/E) ratio of 0.01, which may show that the company is not taking advantage of profits from borrowing. Inhibikase Therapeutics has a current ratio of 7.41, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Inhibikase to invest in growth at high rates of return.Inhibikase Therapeutics Total Current Liabilities Over Time
Inhibikase Therapeutics Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Inhibikase Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Inhibikase Therapeutics Debt Ratio | 2.5 |
Inhibikase Therapeutics Corporate Bonds Issued
Inhibikase Short Long Term Debt Total
Short Long Term Debt Total |
|
Understaning Inhibikase Therapeutics Use of Financial Leverage
Inhibikase Therapeutics' financial leverage ratio measures its total debt position, including all of its outstanding liabilities, and compares it to Inhibikase Therapeutics' current equity. If creditors own a majority of Inhibikase Therapeutics' assets, the company is considered highly leveraged. Understanding the composition and structure of Inhibikase Therapeutics' outstanding bonds gives an idea of how risky it is and if it is worth investing in.
Last Reported | Projected for Next Year | ||
Short and Long Term Debt Total | 622 K | 393.9 K | |
Net Debt | -8.5 M | -9 M | |
Short and Long Term Debt | 224 K | 124.7 K | |
Short Term Debt | 531.9 K | 558.5 K | |
Long Term Debt | 317.9 K | 303.5 K | |
Net Debt To EBITDA | 0.43 | 0.41 | |
Debt To Equity | 0.03 | 0.04 | |
Interest Debt Per Share | 0.07 | 0.07 | |
Debt To Assets | 0.03 | 0.03 | |
Long Term Debt To Capitalization | 0.02 | 0.03 | |
Total Debt To Capitalization | 0.03 | 0.04 | |
Debt Equity Ratio | 0.03 | 0.04 | |
Debt Ratio | 0.03 | 0.03 | |
Cash Flow To Debt Ratio | (47.37) | (49.74) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.